Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200323664> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4200323664 endingPage "S736" @default.
- W4200323664 startingPage "S736" @default.
- W4200323664 abstract "Abstract Background Ceftolozane is a cephalosporin specifically developed to have enhanced antibacterial activity against P. aeruginosa. Combined with tazobactam, it was approved by FDA and EMA for complicated urinary tract and intraabdominal infections, as well as hospital-acquired/ventilator-associated bacterial pneumonia. We evaluated the activity of ceftolozane/tazobactam (C/T) against P. aeruginosa isolates collected as part of the global SMART surveillance program in 10 countries in Latin America. Methods In 2017-2019, 41 clinical labs each collected up to 250 consecutive gram-negative pathogens per year from various infection sources. A total of 21,864 isolates were collected, of which 3,335 (15.3%) were P. aeruginosa. MICs were determined using CLSI broth microdilution and breakpoints. C/T-nonsusceptible (NS) P. aeruginosa isolates were screened for genes encoding β-lactamases. Results The table shows the antimicrobial susceptibility of P. aeruginosa and β-lactam-NS subsets. C/T was active against 85.9% of all collected P. aeruginosa, with lowest activity against isolates collected in Chile and Venezuela, where 28.0% and 23.2% of isolates, respectively, carried carbapenemases, and highest activity against isolates from Ecuador and Guatemala, where 2.2% and 4.2%, respectively, were carbapenemase-positive. Substantial variability in the activity of C/T and comparators was observed among β-lactam-NS subsets. In aggregate, however, C/T remained active against 59.9% of all meropenem-NS P. aeruginosa isolates from Latin America (n=1,101), 57.3% of piperacillin/tazobactam-NS isolates (n=1054), 48.9% of cefepime-NS isolates (n=895), and 50.3% of ceftazidime-NS isolates (n=937). Conversely, other common β-lactams (meropenem, cefepime, ceftazidime, and piperacillin/tazobactam) remained active against 8-38% of these resistant isolates. Results Table Conclusion C/T showed the highest activity against P. aeruginosa among the tested β-lactam antibiotics. While amikacin showed similar or better activity in vitro, its toxicities severely limit its clinical use. Given the desirability of β-lactams among clinicians, C/T represents an important option in the treatment of infections caused by P. aeruginosa in Latin America. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Meredith Hackel, PhD MPH, IHMA (Employee)Pfizer, Inc. (Independent Contractor) C. Andrew DeRyke, PharmD, Merck & Co., Inc. (Employee, Shareholder) Jacquleine Pavía, MSc, Merck & Co, Inc (Employee) Fakhar Siddiqui, PhD, Merck & Co, Inc (Employee) Katherine Young, MS, Merck (Employee) Mary Motyl, PhD, Merck & Co., Inc. (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
- W4200323664 created "2021-12-31" @default.
- W4200323664 creator A5017159626 @default.
- W4200323664 creator A5020290756 @default.
- W4200323664 creator A5035614223 @default.
- W4200323664 creator A5037643218 @default.
- W4200323664 creator A5038009031 @default.
- W4200323664 creator A5042149117 @default.
- W4200323664 creator A5072918748 @default.
- W4200323664 creator A5089366807 @default.
- W4200323664 date "2021-11-01" @default.
- W4200323664 modified "2023-10-18" @default.
- W4200323664 title "1295. Susceptibility to Ceftolozane/Tazobactam and Comparators Among Pseudomonas aeruginosa Isolates Collected from Patients in Hospitals in Latin America – SMART 2017-2019" @default.
- W4200323664 doi "https://doi.org/10.1093/ofid/ofab466.1487" @default.
- W4200323664 hasPublicationYear "2021" @default.
- W4200323664 type Work @default.
- W4200323664 citedByCount "0" @default.
- W4200323664 crossrefType "journal-article" @default.
- W4200323664 hasAuthorship W4200323664A5017159626 @default.
- W4200323664 hasAuthorship W4200323664A5020290756 @default.
- W4200323664 hasAuthorship W4200323664A5035614223 @default.
- W4200323664 hasAuthorship W4200323664A5037643218 @default.
- W4200323664 hasAuthorship W4200323664A5038009031 @default.
- W4200323664 hasAuthorship W4200323664A5042149117 @default.
- W4200323664 hasAuthorship W4200323664A5072918748 @default.
- W4200323664 hasAuthorship W4200323664A5089366807 @default.
- W4200323664 hasBestOaLocation W42003236641 @default.
- W4200323664 hasConcept C176947019 @default.
- W4200323664 hasConcept C2777050379 @default.
- W4200323664 hasConcept C2777637488 @default.
- W4200323664 hasConcept C2777858937 @default.
- W4200323664 hasConcept C2778193466 @default.
- W4200323664 hasConcept C2778266534 @default.
- W4200323664 hasConcept C2779375183 @default.
- W4200323664 hasConcept C2779631663 @default.
- W4200323664 hasConcept C2780950330 @default.
- W4200323664 hasConcept C4937899 @default.
- W4200323664 hasConcept C501593827 @default.
- W4200323664 hasConcept C523546767 @default.
- W4200323664 hasConcept C54355233 @default.
- W4200323664 hasConcept C64778159 @default.
- W4200323664 hasConcept C71924100 @default.
- W4200323664 hasConcept C86803240 @default.
- W4200323664 hasConcept C89423630 @default.
- W4200323664 hasConcept C94665300 @default.
- W4200323664 hasConceptScore W4200323664C176947019 @default.
- W4200323664 hasConceptScore W4200323664C2777050379 @default.
- W4200323664 hasConceptScore W4200323664C2777637488 @default.
- W4200323664 hasConceptScore W4200323664C2777858937 @default.
- W4200323664 hasConceptScore W4200323664C2778193466 @default.
- W4200323664 hasConceptScore W4200323664C2778266534 @default.
- W4200323664 hasConceptScore W4200323664C2779375183 @default.
- W4200323664 hasConceptScore W4200323664C2779631663 @default.
- W4200323664 hasConceptScore W4200323664C2780950330 @default.
- W4200323664 hasConceptScore W4200323664C4937899 @default.
- W4200323664 hasConceptScore W4200323664C501593827 @default.
- W4200323664 hasConceptScore W4200323664C523546767 @default.
- W4200323664 hasConceptScore W4200323664C54355233 @default.
- W4200323664 hasConceptScore W4200323664C64778159 @default.
- W4200323664 hasConceptScore W4200323664C71924100 @default.
- W4200323664 hasConceptScore W4200323664C86803240 @default.
- W4200323664 hasConceptScore W4200323664C89423630 @default.
- W4200323664 hasConceptScore W4200323664C94665300 @default.
- W4200323664 hasIssue "Supplement_1" @default.
- W4200323664 hasLocation W42003236641 @default.
- W4200323664 hasOpenAccess W4200323664 @default.
- W4200323664 hasPrimaryLocation W42003236641 @default.
- W4200323664 hasRelatedWork W2132068732 @default.
- W4200323664 hasRelatedWork W2367815082 @default.
- W4200323664 hasRelatedWork W2582089891 @default.
- W4200323664 hasRelatedWork W2762251864 @default.
- W4200323664 hasRelatedWork W2982248841 @default.
- W4200323664 hasRelatedWork W2984252869 @default.
- W4200323664 hasRelatedWork W3121036438 @default.
- W4200323664 hasRelatedWork W4200090408 @default.
- W4200323664 hasRelatedWork W4200323664 @default.
- W4200323664 hasRelatedWork W4242790524 @default.
- W4200323664 hasVolume "8" @default.
- W4200323664 isParatext "false" @default.
- W4200323664 isRetracted "false" @default.
- W4200323664 workType "article" @default.